Carlos Jaen
Payments from drug & device makers
Across 140 payments — averaging $32.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$827
- GSK$806
- Regeneron Healthcare Solutions, Inc.$655
- Galderma Laboratories, L.p.$376
- Optinose US, Inc.$362
- Sanofi$254
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,515100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $827 |
| GSK | 34 | $806 |
| Regeneron Healthcare Solutions, Inc. | 20 | $655 |
| Galderma Laboratories, L.p. | 5 | $376 |
| Optinose US, Inc. | 8 | $362 |
| Sanofi | 6 | $254 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $219 |
| Pharming Healthcare, Inc. | 9 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $161 |
| Genentech USA, Inc. | 2 | $114 |
| Alk-abello, Inc | 4 | $92 |
| Novartis | 3 | $66 |
| Pfizer | 3 | $57 |
| Lilly USA, LLC | 2 | $55 |
| Biocryst US Sales Co., LLC | 2 | $48 |
| Amgen | 2 | $46 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| Grifols USA, LLC | 1 | $27 |
| CSL Behring | 1 | $25 |
| Incyte Corporation | 1 | $25 |
| Kaleo, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Octapharma USA, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,530 in reported general payments places this provider in the 85th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 33 | $14,009 |
| Levocetirizine Dihydrochloride | 153 | $1,344 |
| Ventolin HfaAlbuterol Sulfate | 12 | $670 |
| Ipratropium Bromide | 18 | $518 |
| Fluticasone Propionate | 42 | $481 |
| Desloratadine | 12 | $325 |
| Ammonium Lactate | 11 | $232 |
| Azelastine Hcl | 12 | $133 |
| Triamcinolone Acetonide | 18 | $110 |
| Famotidine | 33 | $104 |
| Montelukast Sodium | 14 | $84 |
| Prednisone | 11 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $806 | $14,00933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,031 medical providers in Florida.
Other medical in Miami
- Ilanit SamuelsMiami$211K
- Anay CastroMiami$18K
- Polina DasguptaMiami$17K
- Maria SorensenMiami$15K
- Carrie HerzogMiami$14K
- Jesus RodriguezMiami$14K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.